VHC UndervaluedI love how the chart is set up for a long position for 1-day trade. Love that it is trading at +37% of its 50-day volume average, -54% below 200 SMA AMEX:VHC , and RSI of 30 is screaming that it is undervalued. I NASDAQ:LJPC NASDAQ:LJPC
Undervalued
Ally Financial an undervalued stock setting up for a bounceI don't love banking stocks right now because they have so much bad debt on the books, but Ally Financial looks good for at least a short-to-mid-term play. With a P/E of 7.62 and a valuation rating of 94/100 from S&P Global Market Intelligence, Ally looks very attractively valued. It beat estimates and raised guidance on its last earnings report, its earnings grew 10% last quarter vs. the same quarter the previous year. With a 2% dividend yield, Ally offers decent quarterly cash return as well as good growth potential. Best of all, Ally is sitting on a support and looks ready for a bounce from $30 per share. This is definitely my pick of the day.
For more market news, stock analysis, and educational videos for traders, check out my YouTube channel, "Wall Street Petting Zoo."
Has Metcalfe's Law Stopped Working for Bitcoin?Metcalfe's Law has been successfully used to value a variety of network effect technologies and businesses, including Facebook and Tencent.
Applying Metcalfe's Law to Bitcoin , using "Daily Active Addresses" (DAA) as the "n" value, yields interesting results.
Historically, Bitcoin has tracked the Metcalfe Law Fair Price reasonably well. A number of studies have been performed over recent years which validate this and have used various derivations of Metcalfe’s Law. Note: this indicator sticks to the original Metcalf’s Law.
Prior to 2018, every time Bitcoin was above the Metcalfe’s Law fair price (calculated using a default “A” of 0.5 here), a bubble had formed, and price quickly reverted back down to the mean.
Nonetheless, since February 2018, Metcalfe's Law Fair Price has remained below the actual Bitcoin price, suggesting Bitcoin is currently overvalued.
There may be a few reasons for this:
1. Possibility A: Bitcoin may still be extremely overvalued. Since the December 2017 peak, Bitcoin has only reverted to the Metcalfe’s Law Fair Price briefly during the December 2018 bottom. If this case is true, there could be further to fall unless DAA numbers pick up to fill the gap.
2. Possibility B: The introduction of side-chains, private transactions and the Lightning Network may have fundamentally altered the effectiveness of using DAA to value Bitcoin . As more daily transactions are completed off-chain, or on large platforms/exchanges which use fewer addresses, the relative number and growth of DAA may be misrepresented and artificially low. In this case, DAA as it is reported today is no longer useful in assessing the fair value of Bitcoin with Metcalfe’s Law and this Indicator is effectively useless.
3. Possibility C: Neither of the above are true. We are just in an anomalous period in which price and Metcalfe’s Law Fair Price have deviated from the mean for an extended period (and will meet again in the future, potentially at a higher price).
4. Possibility D: Metcalfe’s Law doesn’t really work for Bitcoin .
I am inclined to believe Possibilities “C” and “D” are unlikely. Given the way Bitcoin infrastructure is being developed and used in 2019, Possibility “B” seems the most likely, as this case is supported by the fact that a number of other metrics indicate that Bitcoin is currently on the lower side of “fair value” (including Dynamic Range NVT Signal).
If Possibility “B” is false, or the impact of private network address usage is negligible, the Bitcoin network may not in a healthy state, with DAA values basically flat for the last 3 years.
Regardless, Possibility “A” remains a candidate. Only time will tell. It will be interesting to check back on this indicator in 12-24 months time. Hopefully this indicator has been proven redundant by then.
When to Buy Stocks - S&P 500 Dividend Yield CurveBefore start reading on; this chart is inverted. More on that later
Interpretation
According to Mike Maloney, the S&P 500 dividend yield curve is the second best way to measure a stocks value (after the Shiller S&P500 PE Ratio -made a post on this, go check it out). The ratio indicates how much a company pays out in dividends each year relative to its share price. In other words, it measures how much "bang for your buck" you are getting from dividends. In the absence of any capital gains, the dividend yield is effectively the return on investment for a stock. The lower the dividend yield, the less you get for your investment and hence the more overvalued a stock. The historic S&P 500 Dividend Yields were deducted by Robert Shiller and published in his book Irrational Exuberance.
Why is the chart inverted?
Two reasons
1. This allows you to see, bubbles are up instead of down, and undervalued is down instead of up
2. The higher the yield the more undervalued the stock is, the lower the yield the more overvalued the stock is
Areas of S&P 500 Dividend Yield Curve
Stocks are undervalued: 1% - 4%
Stocks are undervalued: 4% - 5%
Stocks are fair value: 4% - 6%
Stocks are undervalued: 6% +
Keeping an eye on...
The alarming thing when looking at this chart is it has only once ever been this high and that was at the beginning of the millennia and this chart goes all the way back to 1872. As of the time of this writing it is at 1.94. The highest it’s ever been is 1.11. This goes to show the size of the bubble we are currently is.
Note: This "indicator" is used to find the best time to purchase stocks, not to pick or find the market top/bottom
How to “rebalance the dividend yield curve”
Going back to Mike Maloney and his analysis...to bring down this dividend yield he sees two ways the market can seek equilibrium.
1. The market goes sideways for a decade while we have raging inflation that will balance this out and then bring dividend yields and PE’s ratios back into line
2. It crashes, the markets go down
The currency supply collapses, therefore this has to be a deflationary collapse, this cant be an inflation in what they call an invisible crash.
Note that the source of the material here is from 2011
Source: www.youtube.com (58:22)
Beark Creek Mining poised for huge run BCEKFThe year has been good so far for Bear Creek Mining, but as of recent, it has lagged behind it's competitors as the cost of silver has increased. I expect to see that once the 12-day EMA 26-day EMA, we should expect to see the start of a huge uptrend in the stock price. At this point of time with silver jumping above the $18/oz. level, this price is the base price analysis for the Corani Mine which will see huge increases in NPV. Corani NPV increases approximately US $112 M for every $1 increase in silver price (with
proportional increases in lead and zinc), According to a July 2019 power point presentation on Bear Creeks Website. This means that BCEKF is tremendously undervalued due to their ownership of one of the largest silver mines in the world, especially during the beginning of the bull market in silver and gold. Pick up this stock early if you can.
Baidu ready to recover after Q2 resultsThe stock has been in negative Weekly RSI since a few weeks now...
Last time this happened in 2015, the stock had jumped up by 70% after it recovered. In terms of Risk/Return it looks very attractive as the bottom has been hit while the recovery can be significantly interesting.
Fundamentally the stock has been hurt due to global environment (china trade war / economic slow-down) and the business has for the first time seen a real slow down in revenue and earnings (especially due to investment in new tech)
However, currently the valuation fundamentally doesn't make sense.
If you include CTRIP, IQIYI and the 12.5bn cash position. It means that Baidu Core Search engine is currently valued at 10BN
This mean 1x Revenue Multiple / 2x EBITDA Multiple. Not seen many companies trading at 2x EBITDA multiple. Huge undervaluation due to sentiment..
Guardion Health Sciences (GHSI) BounceGHSI recently peaked at $3 and is trading below 50 cents currently. Potential upside is over 60% making this a great buy for anyone looking to ride the wave up. I would not hold beyond 50 cents. Day trade only
ETH IS STUPIDLY UNDERVALUED - PRE-2017 BULLRUN LEVELS. WOWWoah. I think it is hard to judge how the market is really going when you consider the amount of coins that are REALLY low in value, compared to the levels that BTC has managed to jump up too...
Everyone goes on about a no alt-season, however, they do happen it is just a matter of when. But if your a betting man. ETH has a great opportunity to make you some more Bitcoin.
How: % of your profits from BTC into ETH. Accumulate at the bottoms and sell when they reverse = More Bitcoin...
Shiller S&P500 P/E RatioBrief Description About the P/E Ratio
The p/e ratio is the price of a share of a stock divided by the earnings per share, so it’s the earnings that the company makes during a year divided by the number of outstanding shares. Once calculated the answer is a multiple. This is one of the best valuation metrics that investors have been able to use to judge whether they’re buying an overvalued or an undervalued stock.
Using the logic of this fundamental indicator for individual stocks, Dr .Robert Shiller applied this to the S&P 500 , using the S&P 500 as a general gauge of the entire stock market. By doing this, it allowed us to see whether the stock market is undervalued, fair valued, overvalued, and in a bubble, etc.
About the Shiller S&P 500 P/E Ratio
The Shiller p/e ratio is slightly different from the traditional S&P 500 p/e ratio where; instead of dividing by the earnings of one year, this ratio divides the price of the S&P 500 index by the average inflation-adjusted earnings of the previous 10 years. The ratio is also known as the Cyclically Adjusted PE Ratio (CAPE Ratio), the Shiller PE Ratio, or the P/E10.
Areas of the Shiller S&P500 P/E Ratio
As you can see on the chart, there are several different ranges with each one describing the "state" of the stock market
0-5 = stocks are extremely undervalued
5-10 = stocks are undervalued
10-15 = stocks are at fair value
15-20 = stocks are overvalued
20-30 = stocks are in a bubble
30-40 = stocks are in an extreme bubble
Interpreting the Multiple
Think of the multiple this way; you are paying (insert multiple number) times the earnings . Another way to interpret the multiple, it can be counted as the number of years it would take for the individual to get his investment back.
Example #1 : Great Depression, one of the worst times in history, the Shiller S&P 500 p/e Ratio was above 32.56, this means you are paying 32.56 times the earnings , and it would take the investor 32.56 years to get his investment back.
Example #2 : 1998-2000 the Shiller S&P 500 p/e Ratio was 44.19, this means you are paying 44.19 times the earnings , and it would take you the investor 44.19 years to get your investment back, even if they were to give you all of the earnings as dividends you would still have to wait 44.19 years.
That’s insane, that is a lifetime!
“Timing beats speed, precision beats power”
Analyzing the Shiller S&P 500 P/E Ratio
One thing you will notice when doing some analyses of this multiple is the following: whenever the multiple surpasses the 20-30 area, the multiple always returns back to 0-10 area. Once the trend reverses and the bubble pops, it doesn’t stop until the multiple has reached some somewhere in the range of 0-10 (undervaluation) as I have illustrated above with the blue arrows. It does this without exception. It would need to revisit undervaluation before a new “healthy” real bull market were to start again. Once the trend has reversed it doesn’t go straight down, it mimics the movement of a ball rolling down the stairs. You can think of each step of stairs as one of the areas it has to go through before eventually reaching the bottom, similar to how the Fibonacci retracement tool works.
Using this historically repeating pattern, I'd say we are currently on another step down the stairs before we eventually make our way down the bottom of the stairs where we revisit undervaluation areas.
Once have reached the undervaluation areas, this will also be a moment of consolidation where investors, traders, pension fund managers, self-directed IRA owners will have most likely given up and have thrown in the towel. You will most likely see news article titles saying something along the lines of: to invest into the stock market is one of the worst things you could do, but it couldn’t be further from the truth. You can apply this reasoning to all the different kinds of markets and remember these...
"When the time to buy comes, you won’t want too"
"Buy when there’s blood in the streets, even if the blood is your own"
Why has the the multiple so high over the past 20 years or so, well at least why I think it is high
These are some explanations came up with
1 - Interest Rates are Low
Specifically the "Interest Rate - Investment" graph
For those who have taken macroeconomics in college or university, etc know about this graph. Essentially the idea/theory behind this graph is that investments change according to interest rates.
High interest rates = fewer "projects" approved
When interest rates are high, and people want a good return on their investment what do they buy? People buy bonds, not cash, because cash
doesn't earn interest. By having high interest rates, money is "expensive", it isn't readily available. High interest rates = slower economic growth .
Lower interest rates = more "projects" approved
When interest rates are low people are going to do the exact opposite of holding bonds, they are going to hold cash, because the rate of return
is low enough to not put their money in a locked contract for a specified time frame. When interest rates are low, money is "cheap", it is more
readily available. Low interest rates = fast economic growth.
alevelecons.weebly.com
twitter.com
2 - Bond Yields are Low ---> Stock Market
The second reason here ties in with the first one. When interest rates are low, bond yields are low, thus no where else for money to go, except the stock market, the money will flow elsewhere, it will flow to other parts of the economy where investors can get a higher rate of return on their investments compared to the rate of returns of bonds. Buying a bond forces you to be in a locked contract for a specified period of time, with interest rates varying. Whereas, in the stock market there is no locked contract, you have more mobility, very high amounts of liquidity, more mobility and freedom to do as you wish with your money.
Example: say you bought some 10 year US bonds in January 2000, you would be getting somewhere around high 5%-mid 6% on your investment, but remember this contract is for 10 years, your locked in for 10 years, can't move out. Instead of buying 10 year US bonds and getting on average 5-6%, you invested in the stock market (ex: SPY ) you would be getting more, about 7-10% on your investment. Which is more logical?
Bond yields have been dropping from the beginning of the millennia, you can see that from around 1998-present time (link below).
stockcharts.com
These are some explanation I was able to come up with and why I think the multiple has been so high ever since the beginning of the millenia or so, I might be wrong, I might be right, don't really know, but thought i'd just put it out there, that others may see this and can get the gears turning.
Hope you enjoyed the post!
Positive Divergence in MACDFIZZ has been one of the most hated stocks over the last 12 months losing ≈70% market cap.
The float is over 53% shorted currently @ a ratio of 11.52
We can see that there is + divergence from march 2019 till now.
I do not expects FIZZ to stay at its current valuation for much longer considering that the PE is 37% below industry and 55% below the company's 5 year AVG
The company has no debt and the revs, profit and EPS are not consistent with the valuation especially so far below industry due to a lawsuit that has not had a material impact on income statement except court costs.
DCF margin of safety stands at 42% w/ a reverse DCF growth rate of 9.58%
FIZZ is priced perfectly for a buyout and I'm sure PEP and KO are watching, but would they be willing to pay the premium up to fair value is the question.
Inverse HS Breakout *On Watch**Could be a range expansion, but pay close attention to ER on Fri.
Still need the volume confirmation for inverse HS- if it breaks out as inverse HS expected target 181
Undervalued by 24% using YDT method. 10% under 5 Yr PE
5 Yr consecutive div growth; current yield 2.63%
Buying Opportunity On WatchTo see full idea from ST follow me on Tradingview...HBI is undervalued and has been a 5* Stock on MorningStar for some time now, well below their 5* price of 19.25.
3.65 % div yield; and 61% undervalued using DYT; 38.6% margin of safety using DCF.
PE is 11.02, 52% less than industry and 80% less than 5 year PE.
HBI has been in downtrend since 2015, but has already bounced off 10 yr demand line once. While revenue and profits have increased YoY so has debt which is holding it down. Keep an eye on that- as soon as it starts to stabilize/ decrease the SP will go up.
Buying OpportunityUndervalued by 38% using Div Yield Theory, 25% <5 yr PE
-BRK's most undervalued bank holding
-Nearing 30 year demand uptrend line
- 8 years consecutive dividend increases
Buying on SupportUndervalued using Divi Yield Theory by 38%. Currently 5 Star stock from M*.
Buying on support for a long lasting dividend stock, it is not a high dividend bu it has increased for 19 consecutive years and 6.42% growth rate last 5.
Still in downtrend but has already bounced off demand line once. Perfect time to start accumulation.
Ravencoin LongRavencoin seems to be in a great position to go long. Aside from my possibly amateur wave counts, RVN is on a support as well as being oversold using my version of the Mayer Multiple. There's also Bullish MACD divergence as well. Putting all of these together leads me to believe that RVN is a safe buy for now and I don't see much of a reason for it to keep going lower.
JWCA:TSXV - James E Wagner Cultivation: potentially bottomingJWCA:TSXV - James E Wagner Cultivation: after breaking down from the 80c range it was trading in for a couple weeks JWCA has so far found support just above a previous consolidation zone from mid January. watching for a move up above 76c and 80c as potential confirmation. The MJ sector is currently weak still and despite positive news today from their JWC2 facility, it was not able to hold any gains. Price action remains stuck under the 50dma & 200dma, with a potential death cross coming this week on the two averages. While these indicators are not in a bullish setup, I remain long term bullish on the stock.
Near term catalysts: first harvest from phase 1 JWC2 facility which will represent their first harvest for recreational use greatly expanding revenue. Just announced JULY 2 that they doubled the capacity at JWC2, with the next phase getting licensed from Health Canada and will be into production ASAP.
My opinion is this little LP has some great IP in their Growth Storm Technology as well as great quality cannabis and is significantly under valued relative to peers on a capacity basis yet which tend to have lesser quality cannabis.
KROGER(KR) - Does this make for a good large cap buy?This time we have strong fundamental analysis that supports an upcoming bull run. KR's earnings report came out a couple days ago and were 31.72% greater than expected! However, stronger evidence on the technical side is needed to convince me of a good buy. I'll wait on bullish confirmation from the 12 period EMA and evidence of a turnaround from the MACD.
KOHL's(KSS) - good mid cap buying opportunity?KOHL's certainly picked up a lot of attention reaching its high of $75 in late April. RSI is showing it oversold and MACD seems to be turning bullish. If it crosses over the 12 period EMA, this could be even better confirmation of a possible turnaround.
$DVLP is our new 1-cent Cannabis play w/ +800% Revenue Growth &
========================
DVLP (Golden Developing Solutions Inc.)
Alert Price: $0.016
Website | Recent News
Ecommerce: www.puravidavitamins.com
========================
Members,
We're not wasting any time this week.
We've already identified, what is in our opinion one of the biggest steals in the cannabis sector right now.
Please turn your immediate attention to DVLP (Golden Developing Solutions Inc.).
Trading at just over a penny per share, this emerging leader in the Cannabis, Hemp, and CBD marketplace has more upside than most companies operating in the sector.
Global acceptance of cannabis and related CBD products continues to increase as North America advances toward favorable legislation. Canada legalized recreational cannabis in October 2018, and the United States has 30 states and the District of Columbia allowing either recreational or medical cannabis, or both. The global legal cannabis market is projected to reach USD$146 billion by the end of 2025, with a greater acceptance of medical cannabis products as a driving factor, according to Grand View Research.
DVLP is taking advantage of consumer demand for CBD products through its wholly owned Pura Vida Vitamins, LLC subsidiary, which recently launched a direct-to-consumer website (www.PuraVidaVitamins.com) and commenced sales of Pura Vida branded products. Pura Vida merchandise includes hemp and CBD-related products and other products focusing on health and lifestyle which are available through established wholesale and distribution channels.
The Bullish Case for DVLP
Moved into its new 25,000 square-foot production facility in Denver, CO, on June 10, 2019. Management notes that new equipment associated with outfitting the facility is being funded by a new financing agreement that is already in place. Equipment will arrive in the next forty-five (45) days. The Company anticipates a five-fold increase in total production levels in the first three months following delivery and installation.
Signed a Letter of Intent (“LOI”) toward the establishment of a licensing agreement to acquire full and exclusive rights to market and distribute a two-time award-winning proprietary line of energy drinks under the DNA Energy Drink® brand designation. The Company intends to market both CBD-infused and non-CBD energy drinks.
Reported Record 800% Jump in Combined-Entity Revenues for March 2019.
Obtained fully-audited fully-reporting status with the SEC following the filing of audited financial data along with Form 10. In addition, the Company is in the process of uplisting shares from the Pink Sheets onto the OTCQB “Venture Market” tier.
Up-listing to the OTCQB should be good for price, liquidity, and potential appreciation of DVLP.
By moving up to stronger and more recognizable exchanges, the stock will broaden its available shareholder base, some firms, and funds, as some institutions do not invest in stocks listed on the lower tier exchanges.
DVLP sees +800% Revenue Increase
DVLP recently announced that, along with its recent acquisition, Infusionz, LLC (“CBD Infusionz”), that the two business entities have combined to achieve a record $590,488 in monthly revenues during March 2019, representing a massive 800% jump in combined performance on a year-over-year basis when compared to March 2018!
We did the quick math, and if DVLP were to continue this monthly revenue trend, annual revenues would equate to over $7M!
We can't think of any companies generating over $7M per year that are trading at just around 1-cent per share, which leads us to believe that DVLP is one of the most undervalued companies in the cannabis space.
This could be your perfect entry point for DVLP.
DVLP has a history of experiencing significant volatility.
In March DVLP traded as low as 0.0143, subsequently rallying to a high of 0.0269, an upside of more than 88% in just a few weeks.
In early April, we watched shares of DVLP run over +32% from $0.0177 to $0.0235.
Then again in late April, shares of DVLP more than doubled from $0.0142 to over $0.03 in just 3-weeks time.
DVLP is now trading back in the range where we believe its upside potential far outweighs its downside risk.
That being said, we ask that you start your research now, and consider building a position in DVLP tomorrow morning at 9:30AM EST!
About Golden Developing Solutions, Inc.
Golden Developing Solutions (DVLP) is developing an online retail business for cannabidiol (CBD), hemp oil and health/wellness-related products. The Company is also developing a high-capacity, high-quality CBD extraction and production facility. In addition, through the website of its joint venture partner, Pura Vida Vitamins (www.PuraVidaVitamins.com), as well as through wholesale and distribution channels, the Company offers a broad range of high-quality, price-competitive products, including traditional vitamins, supplements, and CBD-based tinctures, vapes and soft gels, among other products. Merchandise also includes hemp and CBD-related products and additional products focusing on health and lifestyle.
Golden Developing Solutions is a development-stage company providing business services and/or products supporting the cannabis industry, in which company intends to make acquisitions in the near future. Currently, 29 states and the District of Columbia have passed laws permitting their citizens to use cannabis for medical and/or recreational purposes. Cannabis has shown encouraging signs as a treatment for various medical conditions and has become increasingly more acceptable to the public and society.
DVLP experienced a remarkable 2018, as the company noted in this announcement:
“Golden Developing Solutions Announces Nationwide Expansion of 'Where's Weed' Following Record Breaking $18 Million in Transactions”
A little about this platform:
“Since 2011, Where’s Weed has been dedicated to helping medical and recreational consumers find dispensaries, delivery services, strains, and deals in their local cannabis community.”
“Additionally, the platform helps cannabis companies connect with consumers and more efficiently manage and market their business in the digital space.”
Furthermore, the company announced:
“Golden Developing Solutions Announces 149% Q4 Rev Growth in “Where’s Weed” Division, Sees Accelerating Platform Growth in Q1 and 2019”
DVLP Acquires CBD Infusionz
DVLP secured powerful traction in the cannabis space as a service provider with their popular Where’s Weed app and portal. And, recently, they expanded this market coverage footprint by moving into the CBD space full force with their Where’s CBD portal, which is beginning to take root as a powerful resource.
That sets the stage for what they feel could be a true gamechanger in the quarters ahead, in terms of synergies and overall augmentation of their core growth proposition: their recent acquisition of Infusionz, LLC (“CBD Infusionz”), a premium manufacturer of high quality CBD products.
Why do they believe this acquisition is such an important move?
First off, it will immediately augment their topline growth data, which is a core factor for institutional investors in search of strong growth potential. They can now offer a better argument given the strong revenues they assume as we onboard CBD Infusionz. For example, if they backdate our analysis, the combined entity would have had total sales of more than $500K in February alone.
In addition, following this acquisition, they have a fully developed retail, wholesale, distribution, and white labeling operation in the CBD space to augment their Where’s CBD services offering.
In fact, with CBD Infusionz operationally integrated, they will now have on offer more than 150 product SKU’s, including vegan products, pet products, pre-rolls, concentrates, creams and lotions, muscle freeze, massage oil, and premium products with existing brand traction such as the Saucy Boss Concentrate line and the Terpy J Pre-roll line.
In short, they emerge from this deal with a powerful value proposition for new investment capital. Their equity is now trading at just 2X our 2019 projected sales, which represents a run rate of $6 million on an annualized basis at current levels. That run rate is also a fixed point on a steep growth curve that shows evidence of a 4-6 month doubling rate at present.
And, perhaps most importantly, they are tethered to arguably the two most robust growth markets on the planet right now in cannabis and CBD. Following this acquisition, they are now more focused on CBD than we have been in the past because the growth curve is even more robust in CBD than it is in cannabis, given the lack of legal barriers to mainstream adoption by consumers in North America. Recent updated forecasts now anticipate a twenty-fold ramp in total sales volume over the next 36 months in the CBD marketplace to over $20 billion, according to several prominent forecasts.
In other words, we believe, with their recent acquisition of CBD Infusionz, they have assembled the pieces of a very strong shareholder value proposition over coming quarters and years.
They will continue to act according to the principles that have taken them this far. They have a number of exciting plans in the works, and they will do their best to keep you updated as they move forward.
Recent Developments
DVLP Announces Move-In Date for New Denver CBD Production Facility
DENVER, June 05, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Golden Developing Solutions, Inc. (DVLP) (“DVLP” or the “Company”), an emerging leader in the Cannabis, Hemp, and CBD marketplace, is pleased to announce that the Company will be officially moving into its new 25,000 square-foot production facility in Denver, CO, on June 10, 2019.
Management notes that new equipment associated with outfitting the facility is being funded by a new financing agreement that is already in place. Equipment will arrive in the next forty-five (45) days. The Company anticipates a five-fold increase in total production levels in the first three months following delivery and installation.
As noted in the Company’s release dated May 20, 2019, the new facility will house primary production for the Company’s wholly-owned subsidiary, Infusionz, LLC (“CBD Infusionz”), a premium manufacturer of high-quality CBD products addressing a wide spectrum of market product niches in the CBD space.
“We are excited to get into the new facility, get organized, and ramp up operations,” commented DVLP CEO Stavros Triant. “This is a massive expansion of our overall production footprint, and we anticipate a correspondingly massive expansion in our growth rate and the value proposition we offer our shareholders. That represents a very strong position for the Company, particularly following passage of Colorado House Bill 1090 last month.”
The Company was excited to receive news of recent bills signed into law by Colorado Governor Jared Polis on May 29, following passage by state legislators in session. House Bill 1090 has particularly strong implications for investments in the Colorado Hemp, Cannabis, and CBD sector, as outlined in a recent piece in the Denver Business Journal. Specifically, the bill allows publicly traded companies to have cannabis licenses and enables more investments in the state’s cannabis industry by venture capitalists and other private equity firms by removing the limit of 15 out-of-state owners per cannabis company.
Mr. Triant continued, “When we acquired CBD Infusionz, the problem they were facing was too much demand and an inability to handle the pace of expansion. That’s the best problem to have in business when you have access to capital and an experienced management team. Colorado is extremely friendly to that mission. The next three months should be the start of a very fun ride.”
Golden Developing Solutions Reports Record 800% Jump in Combined-Entity Revenues for March 2019
DENVER, April 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Golden Developing Solutions, Inc. (DVLP) (“DVLP” or the “Company”), an emerging leader in the Cannabis, Hemp, and CBD marketplace, is excited to announce, along with its recent acquisition, Infusionz, LLC (“CBD Infusionz”), that the two business entities have combined to achieve a record $590,488 in monthly revenues during March 2019, representing a massive 800% jump in combined performance on a year-over-year basis when compared to March 2018.
“We are seeing tremendous validation on a strategic level,” commented DVLP CEO Stavros Triant. “The move to expand our exposure to the CBD space was very well-timed, and is already beginning to pay off. The numbers for March bear that out unmistakably.”
Management notes that this data demonstrate a dramatic growth curve on both an annual and sequential monthly basis, with the comparative March monthly year-over-year and the sequential monthly data showing appreciable growth. As noted above, the year-over-year monthly comparable revenue data increased by 800% while the sequential monthly data showed an increase of nearly 18%, which represents a follow-on annualized growth rate of 630% over the coming 12 months.
According to recent macro analysis of the CBD space, that level of growth is not particularly remarkable given the market context. Analysts have begun to project similar exponential growth in the CBD space over the next 36 months following the signing of the 2018 Farm Bill, which opened the door to a much easier path of mainstream expansion in hemp-based CBD sales in the United States.
“As we integrate CBD Infusionz, we will be dramatically increasing our operational potential,” continued Mr. Triant. “Where’s Weed and Where’s CBD have provided powerful growth catalysts on the services side. But the addition of a true leadership asset on the CBD product side sharply amplifies our growth proposition at an ideal time from an industry standpoint.”
Market Outlook:
Growth of “consumer spending on legal cannabis” is expected to “accelerate in 2019, jumping 38% to $16.9 billion."
This number is expected “to reach $31.3 billion in 2022”.
But the US could provide the sector with an even bigger opportunity.
According to Business Insider, “recreational marijuana is now legal in 10 states; medical marijuana is legal in 33.”
But here is where this gets exciting for the sector, and why there has been so much enthusiasm recently…
According to MarketWatch, members of the US Congress plan to pass a Marijuana Banking Bill in 2019.
This could be another positive catalyst for the sector in the US as regulations further ease.
The movement is gaining traction too…
The “New Marijuana Banking Bill In Congress Has 108 Cosponsors”.
In fact, in a huge development, two weeks ago it was reported by Forbes: “Marijuana Banking Bill Approved By Congressional Committee”
This could be another massively positive catalyst for companies in this sector in the world’s largest economy.
Technical Analysis
As we mentioned above, DVLP has historic volatility, and has reversed hard off these levels time and time again.
It is also trading just slightly above its 52-week low, which leads us to believe that its upside potential far outweighs its downside risk.
In fact, a run back to its 52-week high of $0.16 from today's alert price would net traders over +775% in pure profit!
The Bottom Line
With an +800% revenue increase, and a solid plan for growth, DVLP appears to be grossly undervalued at its current share price.
DVLP has reversed from these levels time and time again.
Those who grab up shares at today's alert price could be handsomely rewarded in the immediate future.
That being said, we ask that all members start their research on DVLP immediately, and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The PennyStock101 Team
Don't Miss Our Next Huge Winner...
Text 'PS101' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by One 22 Media LLC to conduct investor relations advertising and marketing for DVLP. We have previously been compensated ten thousand dollars by One 22 Media LLC to conduct investor relations advertising and marketing for DVLP -which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
$DVLP is our new 1-cent Cannabis play w/ +800% Revenue Growth &=====================================
DVLP (Golden Developing Solutions Inc.)
Alert Price: $0.016
Website | Recent News
Ecommerce: www.puravidavitamins.com
======================================
Members,
We're not wasting any time this week.
We've already identified, what is in our opinion one of the biggest steals in the cannabis sector right now.
Please turn your immediate attention to DVLP (Golden Developing Solutions Inc.).
Trading at just over a penny per share, this emerging leader in the Cannabis, Hemp, and CBD marketplace has more upside than most companies operating in the sector.
Global acceptance of cannabis and related CBD products continues to increase as North America advances toward favorable legislation. Canada legalized recreational cannabis in October 2018, and the United States has 30 states and the District of Columbia allowing either recreational or medical cannabis, or both. The global legal cannabis market is projected to reach USD$146 billion by the end of 2025, with a greater acceptance of medical cannabis products as a driving factor, according to Grand View Research.
DVLP is taking advantage of consumer demand for CBD products through its wholly owned Pura Vida Vitamins, LLC subsidiary, which recently launched a direct-to-consumer website (www.PuraVidaVitamins.com) and commenced sales of Pura Vida branded products. Pura Vida merchandise includes hemp and CBD-related products and other products focusing on health and lifestyle which are available through established wholesale and distribution channels.
The Bullish Case for DVLP
Moved into its new 25,000 square-foot production facility in Denver, CO, on June 10, 2019. Management notes that new equipment associated with outfitting the facility is being funded by a new financing agreement that is already in place. Equipment will arrive in the next forty-five (45) days. The Company anticipates a five-fold increase in total production levels in the first three months following delivery and installation.
Signed a Letter of Intent (“LOI”) toward the establishment of a licensing agreement to acquire full and exclusive rights to market and distribute a two-time award-winning proprietary line of energy drinks under the DNA Energy Drink® brand designation. The Company intends to market both CBD-infused and non-CBD energy drinks.
Reported Record 800% Jump in Combined-Entity Revenues for March 2019.
Obtained fully-audited fully-reporting status with the SEC following the filing of audited financial data along with Form 10. In addition, the Company is in the process of uplisting shares from the Pink Sheets onto the OTCQB “Venture Market” tier.
Up-listing to the OTCQB should be good for price, liquidity, and potential appreciation of DVLP.
By moving up to stronger and more recognizable exchanges, the stock will broaden its available shareholder base, some firms, and funds, as some institutions do not invest in stocks listed on the lower tier exchanges.
DVLP sees +800% Revenue Increase
DVLP recently announced that, along with its recent acquisition, Infusionz, LLC (“CBD Infusionz”), that the two business entities have combined to achieve a record $590,488 in monthly revenues during March 2019, representing a massive 800% jump in combined performance on a year-over-year basis when compared to March 2018!
We did the quick math, and if DVLP were to continue this monthly revenue trend, annual revenues would equate to over $7M!
We can't think of any companies generating over $7M per year that are trading at just around 1-cent per share, which leads us to believe that DVLP is one of the most undervalued companies in the cannabis space.
This could be your perfect entry point for DVLP.
DVLP has a history of experiencing significant volatility.
In March DVLP traded as low as 0.0143, subsequently rallying to a high of 0.0269, an upside of more than 88% in just a few weeks.
In early April, we watched shares of DVLP run over +32% from $0.0177 to $0.0235.
Then again in late April, shares of DVLP more than doubled from $0.0142 to over $0.03 in just 3-weeks time.
DVLP is now trading back in the range where we believe its upside potential far outweighs its downside risk.
That being said, we ask that you start your research now, and consider building a position in DVLP tomorrow morning at 9:30AM EST!
About Golden Developing Solutions, Inc.
Golden Developing Solutions (DVLP) is developing an online retail business for cannabidiol (CBD), hemp oil and health/wellness-related products. The Company is also developing a high-capacity, high-quality CBD extraction and production facility. In addition, through the website of its joint venture partner, Pura Vida Vitamins (www.PuraVidaVitamins.com), as well as through wholesale and distribution channels, the Company offers a broad range of high-quality, price-competitive products, including traditional vitamins, supplements, and CBD-based tinctures, vapes and soft gels, among other products. Merchandise also includes hemp and CBD-related products and additional products focusing on health and lifestyle.
Golden Developing Solutions is a development-stage company providing business services and/or products supporting the cannabis industry, in which company intends to make acquisitions in the near future. Currently, 29 states and the District of Columbia have passed laws permitting their citizens to use cannabis for medical and/or recreational purposes. Cannabis has shown encouraging signs as a treatment for various medical conditions and has become increasingly more acceptable to the public and society.
DVLP experienced a remarkable 2018, as the company noted in this announcement:
“Golden Developing Solutions Announces Nationwide Expansion of 'Where's Weed' Following Record Breaking $18 Million in Transactions”
A little about this platform:
“Since 2011, Where’s Weed has been dedicated to helping medical and recreational consumers find dispensaries, delivery services, strains, and deals in their local cannabis community.”
“Additionally, the platform helps cannabis companies connect with consumers and more efficiently manage and market their business in the digital space.”
Furthermore, the company announced:
“Golden Developing Solutions Announces 149% Q4 Rev Growth in “Where’s Weed” Division, Sees Accelerating Platform Growth in Q1 and 2019”
DVLP Acquires CBD Infusionz
DVLP secured powerful traction in the cannabis space as a service provider with their popular Where’s Weed app and portal. And, recently, they expanded this market coverage footprint by moving into the CBD space full force with their Where’s CBD portal, which is beginning to take root as a powerful resource.
That sets the stage for what they feel could be a true gamechanger in the quarters ahead, in terms of synergies and overall augmentation of their core growth proposition: their recent acquisition of Infusionz, LLC (“CBD Infusionz”), a premium manufacturer of high quality CBD products.
Why do they believe this acquisition is such an important move?
First off, it will immediately augment their topline growth data, which is a core factor for institutional investors in search of strong growth potential. They can now offer a better argument given the strong revenues they assume as we onboard CBD Infusionz. For example, if they backdate our analysis, the combined entity would have had total sales of more than $500K in February alone.
In addition, following this acquisition, they have a fully developed retail, wholesale, distribution, and white labeling operation in the CBD space to augment their Where’s CBD services offering.
In fact, with CBD Infusionz operationally integrated, they will now have on offer more than 150 product SKU’s, including vegan products, pet products, pre-rolls, concentrates, creams and lotions, muscle freeze, massage oil, and premium products with existing brand traction such as the Saucy Boss Concentrate line and the Terpy J Pre-roll line.
In short, they emerge from this deal with a powerful value proposition for new investment capital. Their equity is now trading at just 2X our 2019 projected sales, which represents a run rate of $6 million on an annualized basis at current levels. That run rate is also a fixed point on a steep growth curve that shows evidence of a 4-6 month doubling rate at present.
And, perhaps most importantly, they are tethered to arguably the two most robust growth markets on the planet right now in cannabis and CBD. Following this acquisition, they are now more focused on CBD than we have been in the past because the growth curve is even more robust in CBD than it is in cannabis, given the lack of legal barriers to mainstream adoption by consumers in North America. Recent updated forecasts now anticipate a twenty-fold ramp in total sales volume over the next 36 months in the CBD marketplace to over $20 billion, according to several prominent forecasts.
In other words, we believe, with their recent acquisition of CBD Infusionz, they have assembled the pieces of a very strong shareholder value proposition over coming quarters and years.
They will continue to act according to the principles that have taken them this far. They have a number of exciting plans in the works, and they will do their best to keep you updated as they move forward.
Recent Developments
DVLP Announces Move-In Date for New Denver CBD Production Facility
DENVER, June 05, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Golden Developing Solutions, Inc. (DVLP) (“DVLP” or the “Company”), an emerging leader in the Cannabis, Hemp, and CBD marketplace, is pleased to announce that the Company will be officially moving into its new 25,000 square-foot production facility in Denver, CO, on June 10, 2019.
Management notes that new equipment associated with outfitting the facility is being funded by a new financing agreement that is already in place. Equipment will arrive in the next forty-five (45) days. The Company anticipates a five-fold increase in total production levels in the first three months following delivery and installation.
As noted in the Company’s release dated May 20, 2019, the new facility will house primary production for the Company’s wholly-owned subsidiary, Infusionz, LLC (“CBD Infusionz”), a premium manufacturer of high-quality CBD products addressing a wide spectrum of market product niches in the CBD space.
“We are excited to get into the new facility, get organized, and ramp up operations,” commented DVLP CEO Stavros Triant. “This is a massive expansion of our overall production footprint, and we anticipate a correspondingly massive expansion in our growth rate and the value proposition we offer our shareholders. That represents a very strong position for the Company, particularly following passage of Colorado House Bill 1090 last month.”
The Company was excited to receive news of recent bills signed into law by Colorado Governor Jared Polis on May 29, following passage by state legislators in session. House Bill 1090 has particularly strong implications for investments in the Colorado Hemp, Cannabis, and CBD sector, as outlined in a recent piece in the Denver Business Journal. Specifically, the bill allows publicly traded companies to have cannabis licenses and enables more investments in the state’s cannabis industry by venture capitalists and other private equity firms by removing the limit of 15 out-of-state owners per cannabis company.
Mr. Triant continued, “When we acquired CBD Infusionz, the problem they were facing was too much demand and an inability to handle the pace of expansion. That’s the best problem to have in business when you have access to capital and an experienced management team. Colorado is extremely friendly to that mission. The next three months should be the start of a very fun ride.”
Golden Developing Solutions Reports Record 800% Jump in Combined-Entity Revenues for March 2019
DENVER, April 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Golden Developing Solutions, Inc. (DVLP) (“DVLP” or the “Company”), an emerging leader in the Cannabis, Hemp, and CBD marketplace, is excited to announce, along with its recent acquisition, Infusionz, LLC (“CBD Infusionz”), that the two business entities have combined to achieve a record $590,488 in monthly revenues during March 2019, representing a massive 800% jump in combined performance on a year-over-year basis when compared to March 2018.
“We are seeing tremendous validation on a strategic level,” commented DVLP CEO Stavros Triant. “The move to expand our exposure to the CBD space was very well-timed, and is already beginning to pay off. The numbers for March bear that out unmistakably.”
Management notes that this data demonstrate a dramatic growth curve on both an annual and sequential monthly basis, with the comparative March monthly year-over-year and the sequential monthly data showing appreciable growth. As noted above, the year-over-year monthly comparable revenue data increased by 800% while the sequential monthly data showed an increase of nearly 18%, which represents a follow-on annualized growth rate of 630% over the coming 12 months.
According to recent macro analysis of the CBD space, that level of growth is not particularly remarkable given the market context. Analysts have begun to project similar exponential growth in the CBD space over the next 36 months following the signing of the 2018 Farm Bill, which opened the door to a much easier path of mainstream expansion in hemp-based CBD sales in the United States.
“As we integrate CBD Infusionz, we will be dramatically increasing our operational potential,” continued Mr. Triant. “Where’s Weed and Where’s CBD have provided powerful growth catalysts on the services side. But the addition of a true leadership asset on the CBD product side sharply amplifies our growth proposition at an ideal time from an industry standpoint.”
Market Outlook:
Growth of “consumer spending on legal cannabis” is expected to “accelerate in 2019, jumping 38% to $16.9 billion."
This number is expected “to reach $31.3 billion in 2022”.
But the US could provide the sector with an even bigger opportunity.
According to Business Insider, “recreational marijuana is now legal in 10 states; medical marijuana is legal in 33.”
But here is where this gets exciting for the sector, and why there has been so much enthusiasm recently…
According to MarketWatch, members of the US Congress plan to pass a Marijuana Banking Bill in 2019.
This could be another positive catalyst for the sector in the US as regulations further ease.
The movement is gaining traction too…
The “New Marijuana Banking Bill In Congress Has 108 Cosponsors”.
In fact, in a huge development, two weeks ago it was reported by Forbes: “Marijuana Banking Bill Approved By Congressional Committee”
This could be another massively positive catalyst for companies in this sector in the world’s largest economy.
Technical Analysis
As we mentioned above, DVLP has historic volatility, and has reversed hard off these levels time and time again.
It is also trading just slightly above its 52-week low, which leads us to believe that its upside potential far outweighs its downside risk.
In fact, a run back to its 52-week high of $0.16 from today's alert price would net traders over +775% in pure profit!
The Bottom Line
With an +800% revenue increase, and a solid plan for growth, DVLP appears to be grossly undervalued at its current share price.
DVLP has reversed from these levels time and time again.
Those who grab up shares at today's alert price could be handsomely rewarded in the immediate future.
That being said, we ask that all members start their research on DVLP immediately, and consider building a position tomorrow morning at 9:30AM EST
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by One 22 Media LLC to conduct investor relations advertising and marketing for DVLP. We have previously been compensated ten thousand dollars by One 22 Media LLC to conduct investor relations advertising and marketing for DVLP -which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
HOTH delivers +13% in profits so far & could jump past $8 today!=====================
HOTH (Hoth Therapeutics, Inc.)
Float: 3.86M
Current Price: $6.80
Low: $6.75
High: $7.90
Realistic Gains/Loss: +13.18%
Target Price: $10.00
Chart Analysis
Investor Presentation
Website | Recent News
========================
Members,
Yesterday's low-float Nasdaq listed alert HOTH (Hoth Therapeutics, Inc.) started the day off hot, delivering up +13.18% in realistic profit.
It then appeared that some profit taking took place, and shares pulled back to their day low of $6.70.
HOTH appeared to form a base at those levels and bounced back in the afternoon, nearly closing in the green on heavy volume.
We are banking that this afternoon's momentum will continue on into tomorrow's session.
Especially considering the fact that we don't believe the Street got the full effect of yesterday's news release.
This morning HOTH dropped huge news regarding its positive steps towards getting FDA approval for their game changing treatment for eczema, BioFlexa.
Hoth Therapeutics Forms Wholly Owned Australian Subsidiary, in Preparation of Upcoming Clinical Trials for Atopic Dermatitis Solution
NEW YORK, June 6, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as eczema-as well as dermatological and chronic wound disorders, today announced the formation of its subsidiary, Hoth Therapeutics Australia Pty Ltd, in anticipation to perform clinical trials for atopic dermatitis.
Hoth Therapeutics Australia Pty Ltd will oversee the preparation and execution of Hoth's first clinical trial, known as Efficacy and Safety of BioLexa for the Treatment of Mild-to-Moderate Atopic Dermatitis. The newly formed entity will also be eligible for a significant Research and Development tax rebate. The subsidiary will supervise data management, biostatistical, medical monitoring, quality insurance, regulatory and central laboratory services to support the trial.
"We are excited by the opportunity to work with Australian researchers and members of the international pharmaceutical industry, in regards to the development of our proprietary atopic dermatitis treatment," stated Mr. Robb Knie, CEO of Hoth Therapeutics. "This endeavor is a significant milestone for us, as we move towards clinical trials. Hoth is committed to working diligently with physicians, and regulators in order to successfully pilot our BioLexa Platform to the millions of people that are afflicted with atopic dermatitis."
The subsidiary was formed in connection with Novotech and CoSec Consulting. Headquartered in Australia since 1996 and operating in the Asia Pacific region, Novotech is internationally recognized in the industry as a leading regional full-service contract research organization. Cosec Consulting provides carefully crafted compliance, governance and financial solutions for offshore companies undertaking research and development activities in Australia.
This market friendly news sent shares soaring this morning, but we can only imagine the type of move it will make once it has more eyes on it.
We also noticed that the Level II on this low-float biotech play is extremely thin, and we are anticipating a possible move past $8.00 when all is said and done.
We witnessed some wild swings between $6 and $7 yesterday, with a little more volume HOTH could easily run past $8.
Remember...
HOTH is the perfect candidate for a monster breakout.
The Company:
Has a tight float of 3.86M
Operates in the highly volatile biotech sector. (These Stocks Tend to Move Big On News)
Is listed on the Nasdaq Exchange (High Liquidity)
Has a $10 Price Target (+52% Upside)
HOTH has been on our radar for quite some time now. After IPO'ing at $5.50, HOTH went on a tear, hitting a 52-week high of $13.88.
HOTH's recent pullback has created the ultimate buy the dip opportunity for traders.
We all know how explosive these small-cap biotech stocks can be...
Any type of market friendly news could trigger a huge move in share price.
On Wednesday we watched RWLK jump over +200% on positive FDA news.
With HOTH's tiny 3.2M float, any type of market friendly news could send shares soaring.
HOTH also has several bullish catalysts on the horizon that have us confident that its $10 price-target is well within reach.
Atopic Dermatitis is a large and growing market
Affects more than 32 million patients in the US
10 20% of all pediatric patients suffer from Atopic Dermatitis
Need for new, differentiated therapies
HOTH's BioLexa Platform offers a non corticosteroid approach to inhibit the formation of biofilms, which increases effectiveness of BioLexa in clearing current symptoms and preventing future flare ups
Phase 2 study is currently being designed by renowned doctors and scientists and on track to start enrollment in Australia by end of 2019
Study will test efficacy, safety, and ease of use
On target to complete Phase 2 clinical trial by end of Q1 2020
As you can see, HOTH is operating in an in-demand market and has several promising products in its pipeline.
Can you imagine how high HOTH shares could go if it were to receive FDA approval?
Based on our research, HOTH appears to be well on its way to becoming our next bio-tech alert to breakout for monster gains.
The Bottom-Line
We love these low-float bio-tech alerts.
They have the tendency to breakout faster and bigger than any other sector.
This is the only ticker that should be on your radar today.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Click here to view our full profile on HOTH.
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated twenty thousand dollars by Source 4 Communications LLC to conduct a two-day investor relations advertising and marketing campaign for HOTH. . Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
